CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,915 enrolled
Drug / intervention
Identification of genetic causes of diabetic neuropathic paingenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02783469
NCT02783469N/ACompleted
CompareCT.gov

Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)

University of Dundee·observational·Posted May 26, 2016·Updated Jul 16, 2021

In Brief

An observational study evaluating Identification of genetic causes of diabetic neuropathic pain for Diabetic Neuropathic Pain. Completed, enrolled 1,915 participants across 1 site.

Detailed Summary

In 1997, the global prevalence of diabetes was estimated to be 125 million and this has risen to around 400 million in 2015. In addition diabetes has a number of complications including heart disease, blindness, kidney failure and amputation. This represents a significant burden on healthcare services. Type 2 diabetes (T2D) is caused by a combination of genetic and environmental factors. The aim of GoDARTS is to recruit participants with T2D to a registry to provide a platform with which to investigate the genetics of T2D, its complications and response to treatment. This study will investigate the genetic basis of diabetic neuropathic pain.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Neuropathic Pain
CountriesUnited Kingdom
CollaboratorsWellcome Trust, Diabetes UK

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 26, 2016
Enrollment StartOct 1, 2004
Primary CompletionMay 31, 2009
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.1 years ago

Interventions

Identification of genetic causes of diabetic neuropathic paingenetic